AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00846365 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olmesartan medoxomil-hydrochlorothiazide
Description: Olmesartan medoxomil 20 mg/hydrochlorothiazide 12.5 mg, tablets, orally, and Azilsartan medoxomil and chlorthalidone placebo-matching tablets, orally, once daily for 8 weeks.~If participant does not achieve target blood pressure at Week 4, then the dosage will be increased to olmesartan medoxomil 40 mg/hydrochlorothiazide 25 mg, tablets, orally, once daily for the remaining 4 weeks.
Study NCT01576848 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein
Description: Subjects will receive a drink containing 20 gram intrinsically labelled casein.~Half of the subject are young males (YOUNG)(age between 18 and 35 y) and half of the subjects are elderly males (OLD)(age between 70 and 85 y).
Study NCT01576848 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein + carbohydrate
Description: subjects will receive a drink containing 20 gram intrinsically labelled casein plus 60 gram carbohydrates.~Half of the subject are young males (YOUNG)(age between 18 and 35 y) and half of the subjects are elderly males (OLD)(age between 70 and 85 y).
Study NCT02072200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lodotra®
Description: Single arm will be received below oral 10mg tablet daily and maximum 10mg/d depending on the clinical symptoms and the patient's response
Study NCT03501251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxidectin 8mg
Description: Participants will receive the tablet with clean water and a package of biscuits.
Study NCT03501251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxidectin 8 mg + albendazole 400 mg
Description: Participants will receive the tablets with clean water and a package of biscuits.
Study NCT03501251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxidectin 16 mg
Description: Participants will receive the tablets with clean water and a package of biscuits.
Study NCT06727656 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The combined effect of placebo supplementation and normoxia training on both performance and health at sea-level and altitude conditions.
Study NCT03501251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxidectin 16 mg + albendazole 400 mg
Description: Participants will receive the tablets with clean water and a package of biscuits.
Study NCT03501251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxidectin 24 mg
Description: Participants will receive the tablets with clean water and a package of biscuits.
Study NCT03501251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxidectin 24 mg + albendazole 400 mg
Description: Participants will receive the tablets with clean water and a package of biscuits.
Study NCT03501251 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive the tablet with clean water and a package of biscuits.
Study NCT00392106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propafenone
Description: Anti-arrhythmic drug prescribed for treatment of atrial fibrillation
Study NCT00392106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: flecainide
Description: Anti-arrhythmic drug prescribed for the treatment of Atrial fibrillation
Study NCT00392106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dofetilide
Description: Anti-arrhythmic drug prescribed for treatment of atrial fibrillation
Study NCT00392106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sotolol
Description: Anti-arrhythmic Drug prescribed for treatment of Atrial Fibrillation
Study NCT00392106 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulmonary vein ablation
Description: Electrical isolation of pulmonary vein with high-intensity focused ultrasound
Study NCT00392106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone
Description: Anti-arrhythmic Drug prescribed for the treatment of Atrial Fibrillation
Study NCT02087098 — intervention group
Intervention type: DRUG
Intervention: Solifenacin
Description: Patients with residual OAB symptoms (urge urinary incontinence, urgency, and frequency) after treatment with other antimuscarinics
Study NCT03500978 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer CBT Intervention
Description: Peer specialist delivery of cognitive behavioral therapy intervention over the phone.
Study NCT00721799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Fluorothymidine PET scan
Description: 18F-Fluorothymidine (0.04 - 0.08 mCi / kg to a maximum dose of 5 mCi) administered once intravenously for a positron emission tomography (PET) scan.
Study NCT01548365 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infusion therapy nursing expert service
Description: The ITNE will assess the patient and treatment characteristics and use an evidence based decision making algorithm for the selection of the most suitable VAD.~If the VAD needed is a PICC or a midline ITNE will place it following hospital's protocols. If needed, ITNE will also educate and support patients and next of keens in the maintenance of the device at home.~If other devices such as peripheral catheters, central venous catheters (jugular or subclavian) or venous subcutaneous reservoirs are the preferable VADs for patients and treatment conditions, ITNE will work together with health professionals in charge of patients to activate the usual procedures to place the according device.
Study NCT00003723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Gemcitabine 1000 mg/m\^2 days 1, 8 15 (q 28 days)
Study NCT02394756 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Marketed Soft Contact lens
Description: Replacement schedule every 2 weeks
Study NCT02394756 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Marketed Soft Contact lens
Description: Replacement schedule every 2 weeks
Study NCT02394756 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AIR OPTIX® AQUA
Description: Replacement schedule every 4 weeks
Study NCT02394756 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AIR OPTIX® AQUA
Description: Replacement schedule every 4 weeks
Study NCT02394756 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biofinity®
Description: Replacement schedule every 4 weeks
Study NCT02394756 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biofinity®
Description: Replacement schedule every 4 weeks
Study NCT01399307 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Liposuction
Description: Elective Liposuction
Study NCT00398229 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: s.c. human chorionic gonadotropin (Ovitrelle)
Description: S.C. Ovitrelle 250 mcg once
Study NCT00398229 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: s.c. human chorionic gonadotropin (Ovitrelle)
Description: S.C. Ovitrelle 250 mcg once
Study NCT03025373 — intervention group
Intervention type: OTHER
Intervention: Visuo-acoustic stimulation
Description: Controlled visual and acoustic stimulation in a virtual reality setting
Study NCT00676949 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 5 peptide vaccines of KOC1, TTK, CO16, DEPDC1, MPHOSPH1
Description: 1mg each of 5 peptides with IFA. 4 weekly s.c. administration.
Study NCT00001305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humatrope
Description: Patients receive a subcutaneous injection.
Study NCT01220284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Satraplatin in combo with vinorelbine
Description: * Satraplatin (gelatin capsules) p.o. on days 1 to 5 (from 60 mg/m2 up to 80 mg/m2)~* Vinorelbine (soft capsules) p.o. on days 1, 8 and 15 (from 60 mg/m2 up to 80 mg/m2) The treatment is repeated every 4 weeks.
Study NCT04079504 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ligation of indirect hernia sac
Description: Indirect inguinal hernia sac will be separated from the spermatic cord and contents of the sac will be reduced before ligating it at the deep inguinal ring.
Study NCT04079504 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-ligation of Indirect Inguinal hernia sac
Description: the indirect inguinal hernia sac will be separated from the spermatic cord and reduced/inverted in to the peritoneal cavity through the deep inguinal ring along with its contents.
Study NCT02811770 — intervention group
Intervention type: OTHER
Intervention: kidney biopsy
Study NCT04584788 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Masimo O3 Regional Oximeter
Description: Study sensors will be placed on somatic tissues. Readings will be taken from the tissues underneath the O3 sensors.
Study NCT04386447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: In addition to standard treatment, patients in the experimental arm will receive intravenous OT with dilution of 25 UI or 40 UI OT in 500cc physiological solution NaCl 9%. OT will be administered with continuous pump infusion with 62,5 ml/h. The clinician will have the option to decrease infusion speed based on significant variations in arterial pressure, otherwise, the total 25 UI or 40 UI amount will be infused in 8 hours. Treatment duration will be 10 days
Study NCT04386447 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Standard of Care
Description: Standard of Care (SoC). Standard of Care will comply with the indications of the Emilia-Romagna Region for the treatment of covid-19, and will include the following:~* Oxygen supply or non-invasive ventilation to target peripheral blood saturation > 94%~* Hydroxychloroquine 200mg b.i.d w/o an initial 1-2 days loading dose of 400 mg bid for 1-2 days (the dose may be reduced in patients with advanced CKD according to local protocols) or remdesivir 200 mg in.v on day 1, followed by a 100 mg q.d.~* Antiretroviral therapy (usually for 5 days) with lopinavir / ritonavir or darunavir / cobicistat is permitted~* Azithromycin 500 mg q.d., usually for 5 days, is permitted in patients with suspected bacterial superinfection, paying particular attention to safety, considering reports of risk of adverse events in association with hydroxychloroquine~* Prophylaxis for deep vein thrombosis~* Steroids are not routinely recommended but may be considered in selected patients.
Study NCT00834041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren 3.125 mini-tablets
Description: Oral mini-tablets (3.125 mg) of aliskiren once each morning
Study NCT03918317 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AirXpanders AeroFormtissue expander
Description: The AeroFormdevice will be placed in an immediate fashion at the time of mastectomy in a submuscular, prepectoral or dual-plane approach. The tissue expander will be minimally inflated intraoperatively to minimize dead space and while facilitating tension free closure. Participants will undergo standard postoperative management, and will be given instructions on utilization of the device, including daily expansion until desired volume is reached as determined b surgeon and participant agreement.
Study NCT02632617 — intervention group
Intervention type: OTHER
Intervention: Computed tomographic angiography
Description: Preoperative examination is needed in patients with valvular disease. The invasive coronary angiography is used for patients in ICA group, while the computed tomographic angiography is used as a gatekeeper and invasive coronary angiography is selectively used for patients in CTA group.
Study NCT03826251 — intervention group
Intervention type: PROCEDURE
Intervention: Nasogastric tube removal
Description: Nasogastric tube was removed immediately after surgery
Study NCT02756312 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: IV Anesthesia
Description: The patients will receive intravenous anesthesia
Study NCT02756312 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: IH anesthesia
Description: The patients will receive inhalation anesthesia
Study NCT02490709 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local excision
Description: Local excision for rectal cancer with good response
Study NCT01110265 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: attention training
Study NCT01110265 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo training
Study NCT03231475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH1188-11
Description: qd.po
Study NCT02724683 — intervention group
Intervention type: DEVICE
Intervention: Ascites drainage with vascular catheter.
Description: In case of symptomatic malignant ascites, the procedure of vascular catheter insertion into abdominal cavity will be performed, followed by slow, systematic drainage, on patient's demand.
Study NCT02724683 — intervention group
Intervention type: BEHAVIORAL
Intervention: Interview.
Description: Interview with patients will be performed according to attached chart. The aim is to collect data concerning patient's symptoms, co-morbidity, and basic clinical data about the primary malignancy and treatment status.
Study NCT02724683 — intervention group
Intervention type: BEHAVIORAL
Intervention: Quality of life.
Description: Quality of life questionnaire (QLQ). Patients will be asked to complete QLQ at two time points: 1. immediately before the procedure, 2. one or two weeks after the procedure.
Study NCT02724683 — intervention group
Intervention type: DEVICE
Intervention: Quality of procedure.
Description: Patients will be asked to complete quality of procedure questionnaire at one time point: one or two weeks after the procedure.
Study NCT02724683 — intervention group
Intervention type: OTHER
Intervention: Nutritional status
Description: Risk of malnutrition and ability to feed normally will be assessed with specific questionnaire at two time points: 1. immediately before the procedure, 2. one or two weeks after the procedure.
Study NCT02047266 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MICS CABG
Description: Minimally invasive coronary artery bypass grafting - beating heart multi-vessel procedure in which the anastomoses are performed under direct vision through a lateral left mini-thoracotomy. The left internal thoracic artery is used to graft the left anterior descending artery or circumflex artery territories. Radial artery or saphenous vein are used (Y - grafts) to graft another myocardial territories. Right internal thoracic artery can be used as free Y-graft, as in-situ graft with radial artery (extension technique) or as in-situ graft without composite technique. Right gastroepiploic artery can be used to graft right coronary artery territory. Hybrid approach (MICS CABG + PCI), parallel transfemoral extracorporeal circulation without cardioplegia and CABG from the ascending aorta are acceptable for achievement of the complete revascularization.
Study NCT02047266 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OPCABG
Description: Off-pump coronary artery bypass grafting via sternotomy (aortocoronary bypass grafting or aortic no-touch technique composite grafting). Mechanical Devices are used for coronary artery stabilization and heart positioning. Pericardial traction sutures are used to position the heart where appropriate. Blowers and Intracoronary shunts are used routinely. Anticoagulation is obtained using sodium heparin at a dose of 2mg/kg with supplemental doses to maintain adequate heparinisation (Activated clotting time>250seconds).
Study NCT02047266 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ONCABG
Description: On-pump coronary artery bypass grafting via sternotomy (aortocoronary bypass grafting or aortic no-touch technique composite grafting). Normothermic cardiopulmonary bypass and complex blood ante-retrograde cardioplegia are used. All patients are cannulated with an proximal aortic cannula and two-stage right atrial cannula. Extracorporeal circulation is provided by the Terumo System-1 heart-lung machine using cardiopulmonary bypass systems with physiological surfaces and opened venous reservoirs. The left internal thoracic artery is used to graft the left anterior descending artery, and radial artery or saphenous vein segments are used to graft another myocardial territories. Anticoagulation is obtained using sodium heparin at a dose of 3mg/kg (ACT, activated clotting time>450seconds).
Study NCT02047266 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Octopus® Nuvo, Starfish® Non-Sternotomy, thoracic retractor (ThoraTrak®)
Description: Octopus® Nuvo - MICS CABG tissue stabilizer available for minimally invasive procedures. It minimizes the motion of a small area of the heart while the rest of the heart continues to beat normally and allows to perform anastomosis through a small incision. Starfish® Non-Sternotomy (NS) - MICS CABG heart positioner available for minimally invasive procedures. It allows for the positioning of the beating heart through a small incision, bringing coronary targets into the operative thoracotomy window. ThoraTrak® - a reusable, stainless steel MICS thoracic retractor system for minimally invasive heart surgery with multiple interchangeable blades, which allows to harvest left internal thoracic artery and to perform anastomosis through a small left thoracotomy(Medtronic, Inc., Minneapolis, MN).
Study NCT02047266 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Starfish®, Octopus®, Clearview® blower, ClearView® Shunt
Description: Starfish® - heart positioner is designed to position and to hold the heart to give the surgeon easy access to the vessel requiring the bypass graft. Octopus® - tissue stabilizer minimizes / limits the motion of a small area of the heart while the rest of the heart continues to beat normally. This allows the surgeon to perform CABG surgery without stopping of the heart and without using the heart-lung machine. ClearView® Blower is designed to improve visualization of the surgical site. An irrigation mist gently clears blood from the site, improving visualization without drying or desiccating delicate tissue. The ClearView® shunt - Intracoronary shunt provides a clear anastomotic site during the procedure while providing blood flow to the distal myocardium (Medtronic, Inc., Minneapolis, MN)
Study NCT02047266 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Starfish®, Octopus®, Clearview® blower, ClearView® Shunt
Description: Starfish® - heart positioner is designed to position and to hold the heart to give the surgeon easy access to the vessel requiring the bypass graft. Octopus® - tissue stabilizer minimizes / limits the motion of a small area of the heart while the rest of the heart continues to beat normally. This allows the surgeon to perform CABG surgery without stopping of the heart and without using the heart-lung machine. ClearView® Blower is designed to improve visualization of the surgical site. An irrigation mist gently clears blood from the site, improving visualization without drying or desiccating delicate tissue. The ClearView® shunt - Intracoronary shunt provides a clear anastomotic site during the procedure while providing blood flow to the distal myocardium (Medtronic, Inc., Minneapolis, MN)
Study NCT00662025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1000 mg/m2, twice daily, for 2 consecutive weeks, followed by a 1-week rest period and given as 3-week cycles
Study NCT00662025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib 37.5 mg daily, continuous dosing
Study NCT04560881 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated SARS-CoV-2 vaccine (Vero cell)
Description: Immunization schedule: 2-doses of investigational vaccine or placebo are inoculated to the deltoid muscle of the upper arm according to the immunization schedule of Day 0, 21.
Study NCT04309331 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Motion
Description: Amino acid based protein substitute
Study NCT03908411 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Paratracheal pressure
Description: Paratracheal pressure is applied by 30N force with the ultrasound transducer.
Study NCT03908411 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sellick's maneuver
Description: Conventional Sellick's maneuver is applied by 30N force
Study NCT01740206 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amphetamine and/or methylphenidate
Description: Patients who took their stimulant medication the day of surgery.
Study NCT01740206 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hold stimulant medication
Description: Patients who held their stimulant medication the day of surgery.
Study NCT05074901 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: digital behavioral intervention
Description: interaction with a conversational agent to implement physical and cognitive programs
Study NCT00948545 — intervention group
Intervention type: OTHER
Intervention: Observational study - there is no intervention
Description: Observational study - there is no intervention
Study NCT00322322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Carnitine
Description: L-Carnitine
Study NCT02117518 — intervention group
Intervention type: OTHER
Intervention: blood drawing
Study NCT03621956 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Umbilical Cord Milking
Description: At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 15-20 seconds.
Study NCT03621956 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early Cord Clamping
Description: The umbilical cord is clamped within 30 seconds of delivery.